You just read:

RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.

News provided by

RegeneRx Biopharmaceuticals, Inc.

Feb 27, 2017, 08:30 ET